CellSource Co., Ltd. (JP:4880)
:4880
Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥308.00 - ¥750.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥6.53B
Enterprise Value¥2.31B
Total Cash (Recent Filing)¥4.71B
Total Debt (Recent Filing)¥56.72M
Price to Earnings (P/E)74.0
Beta0.85
Next Earnings
Jun 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)0.53
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.83
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.1
Revenue Forecast (FY)¥3.45B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow financial leverage gives CellSource durable financial flexibility: it can fund R&D, clinical work, and capex without excessive refinancing risk. A conservative balance sheet supports long-term resilience through biotech development cycles and makes the firm a more stable partner for hospitals.
Consistent Positive Cash GenerationSustained operating and free cash flow, even if volatile, indicates the business can self-fund core operations and some investments. Over 2–6 months this supports continued service delivery, consumables supply and steady reinvestment without immediate capital raises, reducing dilution and financing risk.
Specialized, Partnership-driven Business ModelA focused autologous cell-processing model with equipment, consumables and service lines creates recurring revenues and high switching costs for clinical partners. Strategic hospital and research collaborations deepen adoption, supporting durable demand and potential long-term licensing or service margins as the regenerative medicine market matures.
Bears Say
Material Deterioration In ProfitabilitySharply compressed net margins reduce retained earnings available for growth or cushioning setbacks. Persistent margin erosion suggests weaker pricing power or rising costs that could impair returns on invested capital, slow reinvestment into R&D or commercialization, and strain long-term competitiveness.
Volatile Cash Flow And Weakening Cash QualityFluctuating free cash flow and a recent shortfall in cash conversion undermine predictability of funding for clinical programs and capex. Over several months this raises the chance of needing external financing, which can dilute shareholders or increase cost of capital and constrain strategic initiatives.
Inconsistent Revenue Growth And Operating LeverageErratic top-line performance signals demand or execution volatility and weak operating leverage. Inconsistent revenue complicates capacity planning and investment decisions, making it harder to sustain margins and predict multi-quarter cash generation necessary for long-term product rollouts and partnerships.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥308.00 and its highest was ¥750.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.53B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Jun 10, 2026 which is in 4 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Mar 17, 2026. The company reported ¥1.7 earnings per share for the quarter, beating the consensus estimate of N/A by ¥1.7.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.24%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.7 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.571%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. engages in the regenerative medicine-related and consumer businesses. It also offers Signalift, an anti-aging product. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―